



















Fit for Health Support to SMEs & Researchers in FP7 Health-oriented projects

SMEs Instruments in Horizon 2020

5 September 2013 | Bucharest

Rocio Escolano | APRE



Fit for Health is funded by the European Commission

Content of presentation



- SME definition
- SMEs in FP7
- Horizon 2020 SME instrument
 - phase 1
 - phase 2
 - phase 3
- PCP-PPI

Content of presentation



- SME definition
- SMEs in FP7
- Horizon 2020 SME instrument
 - phase 1
 - phase 2
 - phase 3
- PCP-PPI





The SME definition from the European Commission since 01/01/2005:

- ✓ enterprise with interest in business and commerce
- employs fewer = than 250 persons

✓ annual turnover does not exceed EUR 50 million or annual balance-sheet total does not exceed EUR 43 million

✓ autonomous



Complete definition:

http://europa.eu/legislation_summaries/enterprise/busin ess_environment/n26026_en.htm

Guide:

http://ec.europa.eu/enterprise/policies/sme/files/sme_definition/s me_user_guide_en.pdf

Content of presentation




- SME definition
- SMEs in FP7

• Horizon 2020 – SME instrument

- phase 1
- phase 2
- phase 3


• PCP-PPI

The 7th Framework Programme (2007-2013)



The 7th Framework Programme (2007-2013)






7 © Fit for Health, 2013

% SMEs in FP7




%SME share on EU Contribution, 2007-2013 Data of 15/04/2013



Mr.Antoine Mialhe

Health Directorate DG Research and Innovation- European Commission

Funding going to SMEs in Health in %




Mr.Antoine Mialhe Health Directorate DG Research and Innovation European Commission

www.fitforhealth.eu

for Health

Number of SMEs funded in Health

EU funding going to SMEs (excl. IMI)




Mr.Antoine Mialhe Health Directorate DG Research and Innovation European Commission



Number of SMEs supported



Number of SMEs supported and average EU funding (excl. IMI)



Mr.Antoine Mialhe Health Directorate DG Research and Innovation European Commission

Content of presentation



- SME definition
- SMEs in FP7

• Horizon 2020 – SME instrument

- phase 1
- phase 2
- phase 3

• PCP-PPI

The New programme Horizon 2020



THE FRAMEWORK PROGRAMME FOR RESEARCH AND INNOVATION

HORIZ (2020)

13 © Fit for Health, 2013

H2020: European Commission proposal



Excellent science

- European Research Council
 - Frontier research by the best individual teams
- Future and Emerging Technologies
 - Collaborative research to open new fields of innovation

Marie Skłodowska Curie actions

 Opportunities for training and career development

Research infrastructures (including e-infrastructure)

 Ensuring access to world-class facilities

Industrial Technologies

- Leadership in enabling and industrial technologies
 - ICT, nanotechnologies, materials, biotechnology, manufacturing, space
- Access to risk finance
 - Leveraging private finance and venture capital for research and innovation
- Innovation in SMEs
 - Fostering all forms of innovation in all types of SMEs

Societal challenges

- Health, demographic change and wellbeing
- Food security, sustainable agriculture, marine and maritime research & the bioeconomy
- Secure, clean and efficient energy
- Smart, green and integrated transport
- Climate action, resource efficiency and raw materials
- Inclusive, innovative and reflective societies
- Security society

European Institute of Innovation and Technology (EIT)

Spreading Excellence and Widening Participation

Science with and for society

Joint Research Center (JRC)

SME instrument: Key features



- Targeted at all types of innovative SMEs showing a strong ambition to grow (and to develop and internationalize)
- Only SMEs allowed to apply for funding (single company support, but collaboration is certainly advisable)
- Competitive, EU dimension only the best ideas pass
- ✓ Market-oriented, close-to-market activities: 70% co-funding
- Entrance in both Phase 1 and 2
- Embedded in societal challenges and key enabling technologies
- Evaluators: market perspective
- Time to grant*: 400 days in 2008 > 150 days in 2014
- Starting date: early 2014
- ✓ Budget: aprox 5€ billion

Source: Mr.Antoine Mialhe Health Directorate DG Research and Innovation European Commission






- It is proposed to have a Horizontal Call through the Societal Challenges and LEITs for the SME instrument.
- Bottom-up approach and open the possibility for all kinds of cross-challenges/cross-LEITs projects to be submitted.
- In the innovation activities phase II (demonstration, piloting, scaling up) companies will want to combine different technologies and approaches to develop a final product, process or service

SME instrument



SME instrument phases



IDEA Business Coaching through out the project MARKET

17 © Fit for Health, 2013

SME instrument

Fit Fit for Health

Phase 1: Concept and feasibility assessment

Input: Idea/Concept in Business Plan I (~ 10 pages)

Main Activities: Feasibility of concept Risk assessment IP regime Partner search Design study Pilot application

Output: elaborated "Business plan II"

Lump sum: around 50.000 €

~ 6 months

Phase 2: Innovation R&D activities

Input: "Business plan II" + "Description of activities under Phase2" (~ 30 pages)

Main Activities: Development Prototyping Testing Piloting Miniaturisation Scaling-up Market replication

Output: investor-ready "Business plan III"

Output based payments: 1 to 2.5 M€ EU funding

~ 12 to 24 months

Phase 3: Commercialisation

Input: "Business plan III" + Opportunities: 'Quality label' for successful Phase 1 & 2

Easier access to private finance see Access to risk finance: 2 pillar. Support via networking, training, coaching, information, addressing i.a. IP management, knowledge sharing, dissemination

SME window in the EU financial facilities (debt facility and equity facility)

No direct funding



- ✓ Funding : 50.000 € Lump sum
- ✓ Duration: ca. 6 months
- ✓ Call: open Call
- Evaluation: 2 evaluators, Go/ No Go
- ✓ Time To contract: 8-12 weeks

Mr.Antoine Mialhe Health Directorate DG Research and Innovation European Commission





- ✓ Only one application per company per year will be allowed.
- Resubmission of the same proposal shall not be admitted.
- No possibility to apply for part 1 during the submission and/or implementation of a part 2 project
- European Union added value could be an eligibility criterion that can immediately result in exclusion regardless of the quality of the rest of the proposal. This should allow rejecting projects that have clearly no European dimension at an early stage.



- A comprehensive Communication strategy will be developed that clearly outlines the objective and scope of funding under the SME instruments.
- High-potential innovative SMEs shall be attracted to participate, but it will be made very clear that only projects with a truly European dimension have a chance to be funded





- ✓ Funding: 1 to 2.5 million € (higher if justified)
- Duration: 12 months (higher if justified)
- ✓ Call: open Call
- Evaluation: 3 evaluators -> Unanimous Go required
- ✓ GA: output-based funding model (Payments will be made after reaching each milestone.)
- ✓ Time To contract: max 150 days

Mr.Antoine Mialhe Health Directorate DG Research and Innovation European Commission



- Applicants that have presented a **positively** reviewed feasibility report, either developed under part 1 or through other means outside Horizon 2020, shall be able to get grants to realize their innovation project.
- This can include some research, but the focus will be on innovation activities such as demonstration, testing, prototyping, pilot lines, scale-up studies, miniaturisation, design, performance verification etc. and market replication,





Result:

- At the end of part 2 participating companies should have developed a NEW idea (product, process, service) that can be deployed and launched on the market.
- The business innovation plan III to be developed by the end of part 2 will contain a detailed marketing and commercialisation strategy and a financing plan describing how private investment will be used





Only **one** application per company per year will be allowed.

- Resubmission of the same proposal shall not be admitted.
- No possibility to apply for part 2 during the submission and/or implementation of a part 1 project (see possibility to join the scheme at any stage)

Duration:

- The duration should be on average 12 months, but could be longer if desired and justified by the SME.
- Since the scheme will be open at any stage, new entrants can be expected at part two. They will be treated and have to fulfill the same requirements as beneficiaries of part 1

Considering that mainly innovation activities will be supported and to further simplify the process, exclusively a **funding rate of 70%** shall be applied.



Funding:No direct funding

 Objective: Provide support and facilitate access to private finance -> financing instruments

 Coaching: ~ 20 coaching days(5 days for phase 1, 15 days for phase 2)

Mr.Antoine Mialhe Health Directorate DG Research and Innovation European Commission

Objective:

- This part aims to promote the implementation and successful commercialisation of innovative solutions by facilitating access to private capital and first customers as well as offering support services.
- The SME instrument with business-oriented evaluation and selection at stages 1 and 2 will provide for a competition at EU level allowing only projects of the highest quality and with the highest commercialisation potential to be funded.
- Successful completion of parts 1 and 2 should therefore constitute in itself a "quality label" being conducive to market uptake and private investment.

Result:

 In this stage the companies should successfully place an innovation (product, process, service etc.) on the market





Financing instruments (EC support through EIF)



- Equity instrument for innovative SMEs:
 - Seed, start-up, early stage, expansion & growth phase
 - Target: indirect support to 1,000 SMEs
- Debt instrument for innovative SMEs:
 - Loan guaranteesfor small and mid caps
 - Target: indirect support to 3,000 SMEs
- Large organisations:
 - Loans & guarantees services
 - Current RSFF: 1b€leveraged9b€of loans

Mr.Antoine Mialhe Health Directorate DG Research and Innovation European Commission

Content of presentation



- SME definition
- SMEs in FP7
- Horizon 2020 SME instrument
 - phase 1
 - phase 2
 - phase 3
- PCP-PPI



www.fitforhealth.eu

Pre-Commercial Procurement (PCP) Public Procurement of Innovative Solutions (PPI)

- ✓ Societal Challenges: The activities sall cover the full cycle from research to market, with a new focus on innovation-related activities, such as support for public procurement
- Industrial Leadership: the support PCP and PPI are all aspects that are essential in addressing competitiviness
- ✓ SME instrument: may connect to measures promoting PPC and PPI
- Support will be provided to PCP by Research Infrastructure actors to drive forward innovation and act as early adopters of technologies



Pre-Commercial Procurement (PCP) Public Procurement of Innovative Solutions (PPI)

Rules for Participation (Article 2)

✓ PCP: 'pre-commercial procurement'means procurement of research and development services involving risk-benefit sharing under market conditions, and competitive development in phases, where there is a separation of the research and development phase from the deployment of commercial volumes of end-products

✓ PPI: 'public procurement of innovative solutions' means procurement where contracting authorities act as a launch customer for innovative goods or services which are not yet available on a large-scale commercial basis, and may include conformance testing

Questions





32 © Fit for Health, 2013

Contact details





Thank you!

Rocio Escolano

The Agency for the Promotion of European Research

Rome, Italy

escolano@apre.it www.apre.it

33 © Fit for Health, 2013

The copyright © is owned by the author of this document. Please do not duplicate. Disclaimer: The "Fit for Health" project partners do not assume any legal liability or responsibilities for the information provided in this document